Immunovant IMVT-1402 CLE Trial Miss
Analysis based on 7 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The failure of IMVT-1402 in cutaneous lupus erythematosus removes a near-term indication from Immunovant's pipeline and may pressure shares of both Immunovant and its majority owner Roivant, though the company's decision to halt only this program limits the damage. Because other IMVT-1402 development timelines remain on track, the market impact is likely contained to modest negative sentiment around the FcRn franchise rather than a broad repricing of the pipeline.
Immunovant announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The randomized, double-blind, placebo-controlled global study enrolled 57 adult patients who were randomized to IMVT-1402 or placebo for a 12-week treatment period. The trial did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at Week 12. Numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. IMVT-1402 demonstrated a favorable safety and tolerability profile consistent with prior studies. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development of IMVT-1402 in CLE, as the study did not meet its internal bar. Immunovant remains focused on advancing IMVT-1402 across other autoimmune indications including Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogren's disease, and stated all other clinical development timelines remain on track. Roivant, Immunovant's majority owner, announced the results. CEO Eric Venker thanked patients, investigators, and clinical site teams.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard